TransThera Biosciences closes Series C round led by CMG-SDIC Fund

On July 22, TransThera Biosciences announced the completion of a Series C round led by CMG-SDIC Fund.

On July 22, TransThera Biosciences announced the completion of a Series C round led by CMG-SDIC Fund.

The round also saw participation from Oceanpine Healthcare Fund, SDIC Venture Capital, Nanjing Fengling Investment, Ennovation Ventures, Eastern Handson, and existing investors Golden Partners Capital and Grand Yangtze Capital.

With the previous Series B funding round, the total amount of funding raised in the two rounds of the company reaches over 60 million US dollars.

TransThera Biosciences is a clinical-stage, platform-based, innovative small molecule drug development company. Its team has extensive experience in preclinical biology, pharmacology and pharmacology, as well as comprehensive clinical development capabilities and resources.

The company is committed to building a rich portfolio of First-in-Class and Best-in-Class products in response to unmet clinical needs in the fields of oncology, cardiovascular and metabolic diseases, driven by independent R&D and collaborative innovation.

Dr. Wu Yongqian, Chairman and Chief Executive Officer of TransThera Biosciences, said, “The proceeds from this financing round will be used to rapidly advance the global clinical development of our core products, accelerate the commercialization and internationalization of the company, while continuing to diversify our product pipeline and create sustainable long-term value for our shareholders.”

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/07/25/transthera-biosciences-closes-series-c-round-led-by-cmg-sdic-fund/.

Leave a Reply

Please Login to Comment